Overview
Theradex Oncology provides full-service contract research organization support for cancer trials across all indications and modalities, backed by MD oncologists, regulatory experts, and experienced operations teams. It runs trials from start-up to close-out by combining medical oversight, regulatory submissions, clinical monitoring, data management, and site operations. Its distinct advantage comes from deep oncology specialization, decades of hands-on experience with biotech and pharma sponsors, and a track record with NCI-supported studies. Its goal is to help sponsors conduct efficient, compliant trials and generate reliable data to advance new cancer therapies to patients.
Work here?Claim your company
Simplify's take
What believers are saying
- Theradex posted 2026 hiring for CRAs, signaling active study demand and expansion.
- LinkedIn shows 51-200 employees and 179 visible staff, supporting a focused operating model.
- Theradex attended ASCO, AACR, and BIO in 2026, strengthening sponsor lead generation.
What critics are saying
- Theradex depends heavily on oncology outsourcing; sponsor pauses hit utilization within one quarter.
- Competitors like ICON, Parexel, and Medpace sell broader CRO bundles and deeper capital.
- One lost NCI CTMS renewal after 2032 would threaten Theradex’s institutional credibility and revenue.
What makes Theradex Oncology unique
- Theradex has monitored NCI cancer trials continuously since 1982, extending to May 2032.
- Theradex employs 170 oncology experts, including 17 full-time oncologists and PhDs, in 2026.
- Theradex offers full-service oncology CRO work, from Pre-IND through Phase III globally.
Help us improve and share your feedback! Did you find this helpful?